FDA orders new warning about GLP-1's

The FDA says it will require all GLP-1s, the popular weight loss drug, to adjust their warning labels. This coming after research showed patients on it have increased potential for developing a rare eye condition which can cause vision loss. Fox's Natalie Chuck has more from Los Angeles. The Food and Drug Administration is placing a new safety warning on popular weight loss drugs like Ozempic and Wegovy, also known as GLP-1s. New research shows they carry a small risk of users developing permanent vision loss. The data is pretty convincing that there is an association. It's pretty consistent over multiple studies. The agency reviewed 126 clinical trials with more than 134,000 patients and discovered some taking the prescription drugs experienced an eye condition called non-arteritic anterior ischemic optic neuropathy. It's when blood flow to the optic nerve is reduced However, the underlying cause is not completely understood. It's like a stroke of the eye. You have less blood flow that is nurturing the optic nerve, and the retinal ganglion cells die and causes decreased vision. Research found it's a very rare side effect, impacting about six people out of 100,000 who take a GLP-1. But whatever vision is lost will likely not come back. Over the long term, it's going to stabilize at whatever it's going to, the vision is going to be and you're not going to improve much. There are also other factors which could lead to vision loss, including diabetes, high blood pressure and sleep apnea, common issues among many GLP-1 users. So the FDA noted the GLP might not be solely responsible. If you're suspecting something, then obviously you should get an examination immediately. Moving forward, the FDA said risk of vision loss will be added to all GLP-1 drug labels. In Los Angeles, Natalie Chuck, Fox News.